Inactive Instrument

GI Dynamics, Inc. Australian S.E.

Equities

GID

AU000000GID7

GI Dynamics : Briefing Call and Webcast on Financial Results for Q3 2014

October 27, 2014 at 06:50 pm EDT

Microsoft Word - GI Dynamics - ASX Annoucement -3Q14 Call Webcast - 28-Oct-14

GI Dynamics, Inc. - ASX Announcement

GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Third Quarter 2014

LEXINGTON, Massachusetts & SYDNEY, Australia - 28 October 2014 - GI Dynamics,Inc. (ASX: GID) will hold a conference call to discuss the company's financial results for the third quarter and six months ended 30 September 2014, and its business outlook. Michael D. Dale, president and chief executive officer, will host the call with Robert Crane, chief financial officer.
The company will file its Appendix 4C with the ASX on Friday, 31 October 2014 (AEST). The briefing call to discuss financial results and business updates will be held at 5 p.m. U.S. EST on Tuesday, 4 November 2014 (9 a.m. AEST on Wednesday, 5 November 2014).

Accessing the Briefing Call via Webcast:

A live webcast of the call will be available on the GI Dynamics website at investor.gidynamics.com. The webcast can be directly accessed at: http://edge.media-server.com/m/p/f7u6k33y/lan/en

Accessing the Briefing Call via Telephone:

For those preferring to listen by telephone, please dial in five minutes prior to the start of the call and provide the passcode 38279268. Regional dial-in numbers are as follows:
• United States callers please dial toll-free 1 (888) 771-4371
• Australia callers please dial toll-free 1 (800) 507-265
• International callers please dial 1 (847) 585-4405

Replay archive:

The webcast will be archived for 30 days following the call on the GI Dynamics website at investor.gidynamics.com.

About GI Dynamics

GI Dynamics, Inc. (ASX: GID) is the developer of EndoBarrier®, the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially

available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. GI Dynamics is conducting a pivotal clinical trial

of EndoBarrier in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are

obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit http://www.gidynamics.com/www.gidynamics.com.

Investor Enquiries: Media Enquiries:

United States:

Robert Crane, Chief Financial Officer

+1 (781) 357-3250

United States/Europe:

Dan Budwick, Pure Communications Inc.

+1 (973) 271-6085

Australia:

David Allen or John Granger, Hawkesbury Partners

Pty Limited

+61 2 9325 9046

Australia:

Angela Ceberano, Flourish PR

+61 3 9092 8445

www.gidynamics.com

US OFFICE & HEADQUARTERS: 25 Hartwell Avenue, Lexington MA 02421 T +1 (781) 357-3300 F +1 (781) 357-3301

EUROPEAN OFFICE: De Tweeling 20-22 's-Hertogenbosch 5215 MC, THE NETHERLANDS T: + 31 13 547 9300

AUSTRALIAN OFFICE: Level 8, 17-19 Bridge Street, Sydney, NSW 2000 T +61 2 9325 9046

GI Dynamics, Inc., is a corporation incorporated in Delaware, USA, whose stockholders have limited liability. ARBN 151 239 388

distributed by

Latest news about GI Dynamics, Inc.

GI Dynamics, Inc. Announces First Patient Enrolled in the I-STEP Clinical Study of EndoBarrier in India	23-02-13	CI
GI Dynamics, Inc. Announces Final Data from the ENDO Trial, Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity	22-06-15	CI
GI Dynamics Inc. Announces Approval of the I-STEP Clinical Study in India	22-01-31	CI
Gi Dynamics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-07	CI
Gi Dynamics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-12	CI
GI Dynamics, Inc. Auditor Raises 'Going Concern' Doubt	21-03-11	CI
GI Dynamics, Inc. Announces Termination of Charles Carter as Treasurer and Secretary	21-01-15	CI
GI Dynamics, Inc. Announces Termination of Charles Carter as Chief Financial Officer	21-01-15	CI
Gi Dynamics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-10	CI
GI Dynamics, Inc. Announces CEO Changes	20-11-06	CI
GI Dynamics, Inc. Announces Management Changes	20-11-06	CI
GI Dynamics, Inc. Announces Executive Changes	20-10-26	CI
GI Dynamics, Inc. Announces the Appointment of Joseph Virgilio as its Chief Operating Officer	20-10-15	CI
Transcript : GI Dynamics, Inc. - Shareholder/Analyst Call	20-09-03
GI Dynamics, Inc. Announces Board Resignations	20-08-10	CI
Gi Dynamics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-07	CI
GI Dynamics, Inc. announced that it has received $0.5 million in funding from Crystal Amber Asset Management Limited	20-08-03	CI
GI Dynamics, Inc. announced that it expects to receive funding from Crystal Amber Asset Management Limited	20-08-02	CI
GI Dynamics, Inc. announced that it expects to receive $9.25 million in funding from Crystal Amber Asset Management Limited	20-07-19	CI
Transcript : GI Dynamics, Inc. - Shareholder/Analyst Call	20-06-20
GI Dynamics, Inc. announced that it has received $0.75 million in funding from Crystal Amber Asset Management Limited	20-06-17	CI
Gi Dynamics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-06	CI
GI Dynamics, Inc. Enters into Sixth Amendment to the Senior Secured Convertible Promissory Note	20-03-31	CI
GI Dynamics, Inc. Announces Change to Board of Directors	20-03-29	CI
GI Dynamics, Inc. Auditor Raises 'Going Concern' Doubt	20-03-26	CI

Chart GI Dynamics, Inc.

Duration

Period

More charts

Company Profile

GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.

Sector

More about the company